The following excerpt is from the company's SEC filing.
For further information please contact:
+1 781 482 9502
+44 1256 894157
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic condi tions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.
To receive a free e-mail notification whenever Shire plc makes a similar move, sign up!
Other recent filings from the company include the following:
Shire: Not For Release, Publication Or Distribution In Whole Or In Part In, Into Or From Any Jurisdiction Where To Do So Would Constitute A Violation Of The Relevant Laws Or Regulations Of That Jurisd - July 19, 2018
Shire: Not For Release, Publication Or Distribution In Whole Or In Part In, Into Or From Any Jurisdiction Where To Do So Would Constitute A Violation Of The Relevant Laws Or Regulations Of That Jurisd - July 12, 2018
- Shire Plc (Lse: Shp, Nasdaq: Shpg) (The “Company”), In Accordance With 5.6.1R Of The Financial Conduct Authority'S (The “Fca”) Disclosure Guidance And Transparency Rules, Notifies The Market Of The - July 5, 2018
Major owner of Shire plc just picked up 183,619 shares - July 2, 2018
Annual report of employee stock purchase, savings and similar plans - June 29, 2018